Angiotensin II promotes aortic valve thickening independent of elevated blood pressure in apolipoprotein-E deficient mice

作者：Fujisaka Tomohiro; Hoshiga Masaaki^*; Hotchi Junko; Takeda Yoshihiro; Jin Denan; Takai Shinji; Hanafusa Toshiaki; Ishizaka Nobukazu

来源：Atherosclerosis, 2013, 226(1): 82-87.

DOI：10.1016/j.atherosclerosis.2012.10.055

• Aortic valve
• Atherosclerosis
• Angiotensin
• Hypertension

Background: Valvular aortic stenosis (AS) is not an infrequent condition in the aged population. Activation of renin-angiotensin system (RAS) is presumed to be involved in the development of AS; however, direct evidence seems to be limited. We herein examined the effect of the administration of angiotensin II (Ang II) on the development of aortic valve thickening in apolipoprotein-E (ApoE)-deficient mice.
Methods and Results: Male ApoE-deficient mice were divided into three groups: control (saline, n = 8), mice that were administered low-dose Ang II (500 ng/kg/min, n = 11), and those with high-dose Ang II (1000 ng/kg/min, n = 11) administration for 4 weeks. Administration of high-dose, but not low-dose, Ang II significantly induced aortic valve thickening. It was found that in the aortic valve leaflets of high-dose Ang II group, integrity of endothelial cells was impaired and the number of myofibroblasts was increased. These phenomena induced by high-dose Ang II were suppressed by Ang II type 1 receptor blocker olmesartan (n = 15), but not by the dilatator, hydralazine (n = 13). Olmesartan also suppressed dilatation of aortic diameter, although it did not significantly affect the plaque area, in the abdominal aorta in ApoE-deficient mice.
Conclusion: Administration of Ang II to genetically hyperlipidemic mice induced aortic valve thickening by a pressor-independent mechanism. Role of RAS activation in the development of AS in dyslipidemic patients should further be investigated.

• 出版日期2013-1